Published in Support Care Cancer on March 24, 2011
Integration of oncology and palliative care: a systematic review. Oncologist (2014) 2.20
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
Interdisciplinary palliative care intervention in metastatic non-small-cell lung cancer. Clin Lung Cancer (2013) 0.89
Towards integration of palliative care in patients with chronic heart failure and chronic obstructive pulmonary disease: a systematic literature review of European guidelines and pathways. BMC Palliat Care (2016) 0.87
Palliative care consultation service and palliative care unit: why do we need both? Oncologist (2012) 0.83
Palliative care needs, symptoms, and treatment intensity along the disease trajectory in medical oncology outpatients: a retrospective chart review. Support Care Cancer (2013) 0.80
Palliative care for severely affected patients with multiple sclerosis: when and why? Results of a Delphi survey of health care professionals. J Palliat Med (2014) 0.78
A Review of Integrative Medicine in Gynaecological Oncology. Geburtshilfe Frauenheilkd (2016) 0.78
Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist (2016) 0.78
Need for palliative care for neurological diseases. Neurol Sci (2016) 0.77
To what degree is palliative care integrated in guidelines and pathways for adult cancer patients in Europe: a systematic literature review. BMC Palliat Care (2016) 0.77
Improving Palliative Cancer Care. J Adv Pract Oncol (2015) 0.75
Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014. PLoS One (2017) 0.75
Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting. J Neurooncol (2017) 0.75
Background and design of the symptom burden in end-stage liver disease patient-caregiver dyad study. Res Nurs Health (2017) 0.75
Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med (2010) 29.06
Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA (2008) 11.32
Availability and integration of palliative care at US cancer centers. JAMA (2010) 4.51
Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol (2009) 3.36
Late referrals to specialized palliative care service in Japan. J Clin Oncol (2005) 2.74
Patient navigation in breast cancer: a systematic review. Cancer Nurs (2010) 2.30
Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. J Clin Oncol (2010) 1.87
Dying and decision making--evolution of end-of-life options. N Engl J Med (2004) 1.86
Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med (2005) 1.67
NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw (2009) 1.66
A qualitative study of oncologists' approaches to end-of-life care. J Palliat Med (2008) 1.49
Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol (2007) 1.42
Dealing with conflict in caring for the seriously ill: "it was just out of the question". JAMA (2005) 1.40
Dignity. J Palliat Med (2008) 1.39
Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology (2000) 1.30
Differential palliative care issues in patients with primary and secondary brain tumours. Support Care Cancer (2009) 1.18
Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med (2007) 1.14
Evaluation and comparison of two prognostic scores and the physicians' estimate of survival in terminally ill patients. Support Care Cancer (2009) 1.05
Uncertainty in breast, prostate, and colorectal cancer: implications for supportive care. J Nurs Scholarsh (2008) 1.01
Impact of a palliative care service on in-hospital mortality in a comprehensive cancer center. J Palliat Med (2006) 0.95
Recommending early integration of palliative care - does it work? Support Care Cancer (2011) 0.93
Identifying factors affecting utilization of an inpatient palliative care service: a physician survey. J Palliat Med (2009) 0.92
End-of-life care: lessons from other nations. J Palliat Med (2005) 0.90
Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer (2006) 0.89
Stigma associated with "palliative care": getting around it or getting over it. Cancer (2009) 0.87
Transitions to palliation: two solitudes or inevitable integration? Curr Oncol Rep (2007) 0.87
Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific Guidelines. Breast Care (Basel) (2011) 0.84
Prognosticating: the end of a series. Introduction. J Palliat Med (2008) 0.83
Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project. J Palliat Med (2010) 0.82
Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project. Breast Care (Basel) (2011) 0.82
Specifying WHO recommendation: moving toward disease-specific guidelines. J Palliat Med (2010) 0.81
Humpty-Dumpty Syndrome. Palliat Med (2007) 0.80
Can guidelines be integrated into everyday practice? The NCCN in year 4. National Comprehensive Cancer Network. J Natl Cancer Inst (1999) 0.76
Evidence-based pain management and palliative care in issue one for 2010 of the Cochrane Library. J Pain Palliat Care Pharmacother (2010) 0.75
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med (2014) 6.80
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol (2010) 3.26
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2011) 3.21
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood (2005) 3.14
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2012) 3.00
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med (2002) 2.04
Palliative Care of Adult Patients With Cancer. Dtsch Arztebl Int (2015) 2.02
Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf (2012) 2.00
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2009) 2.00
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood (2005) 1.85
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst (2007) 1.69
Recent developments in adeno-associated virus vector technology. J Gene Med (2008) 1.66
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood (2012) 1.58
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol (2010) 1.57
In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther (2003) 1.53
Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation (2004) 1.50
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol (2013) 1.49
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther (2006) 1.49
B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood (2012) 1.47
Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage (2013) 1.44
A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol (2009) 1.43
High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage (2008) 1.41
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41
Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol (2009) 1.40
Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol (2004) 1.40
Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol (2005) 1.36
Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol (2006) 1.35
Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia (2010) 1.35
Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med (2006) 1.35
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol (2005) 1.34
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res (2005) 1.32
Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol (2003) 1.32
Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.31
Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30
Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol (2002) 1.27
The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol (2008) 1.26
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood (2009) 1.25
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood (2005) 1.24
The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol (2005) 1.22
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood (2002) 1.21
Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther (2004) 1.20
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood (2009) 1.20
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol (2004) 1.20
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol (2007) 1.19
Differential palliative care issues in patients with primary and secondary brain tumours. Support Care Cancer (2009) 1.18
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood (2013) 1.16
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica (2005) 1.15
The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity? J Neurol Sci (2008) 1.15
A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol (2003) 1.15
Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol (2008) 1.14
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol (2008) 1.13
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood (2002) 1.10
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol (2014) 1.10
Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res (2011) 1.09
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood (2013) 1.09
Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology (2012) 1.08
Episodic breathlessness: a clinically relevant and rising issue. Ann Am Thorac Soc (2014) 1.08
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol (2011) 1.07
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res (2005) 1.06
Posaconazole concentrations in the central nervous system. J Antimicrob Chemother (2008) 1.06
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol (2012) 1.06
Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology (2004) 1.05
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med (2013) 1.05
mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest (2013) 1.03
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.03
Issues and needs in end-of-life decision making: an international modified Delphi study. Palliat Med (2011) 1.02
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res (2010) 1.02
The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02
Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol (2008) 1.00
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol (2006) 1.00
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2012) 1.00
Non-cancer patients in specialized palliative care in Germany: what are the problems? Palliat Med (2010) 1.00
Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis (2009) 0.99
Undergraduate training in palliative medicine in Germany: what effect does a curriculum without compulsory palliative care have on medical students' knowledge, skills and attitudes? Palliat Med (2007) 0.99
Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother (2006) 0.97
Single virus tracing: visualization of the infection pathway of a virus into a living cell. Chemphyschem (2002) 0.97
Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood (2008) 0.97
Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol (2005) 0.96
Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs (2004) 0.96
AAV-based gene transfer. Curr Opin Mol Ther (2003) 0.96
Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology (2009) 0.96